Holen Sie sich die Stockscreener-App
0.5789
5.31%
0.0292
Handel nachbörslich:
.57
-0.0089
-1.54%
Schlusskurs vom Vortag:
$0.5497
Offen:
$0.5406
24-Stunden-Volumen:
3.37M
Relative Volume:
0.95
Marktkapitalisierung:
$99.94M
Einnahmen:
$126.33M
Nettoeinkommen (Verlust:
$-82.68M
KGV:
-0.4669
EPS:
-1.24
Netto-Cashflow:
$-79.98M
1W Leistung:
-16.31%
1M Leistung:
-31.67%
6M Leistung:
-37.07%
1J Leistung:
-59.23%
1-Tages-Spanne:
$0.5406
$0.62
1-Wochen-Bereich:
$0.5406
$0.7052
52-Wochen-Spanne:
$0.54
$2.05
Seres Therapeutics Inc Stock (MCRB) Company Profile
Firmenname
Seres Therapeutics Inc
Sektor
Branche
Telefon
617 945 9626
Adresse
200 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie MCRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| MCRB | 0.5789 | 99.94M | 126.33M | -82.68M | -79.98M | -1.24 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-21 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-23 | Herabstufung | Goldman | Neutral → Sell |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-03-05 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-11 | Hochstufung | Jefferies | Hold → Buy |
| 2019-04-30 | Eingeleitet | Jefferies | Hold |
| 2018-10-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-08-04 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-01 | Bestätigt | FBR & Co. | Outperform |
| 2016-08-12 | Bestätigt | FBR Capital | Outperform |
| 2016-08-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Bestätigt | H.C. Wainwright | Buy |
| 2016-07-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-03-30 | Eingeleitet | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | Guggenheim | Buy |
| 2016-01-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-10-22 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-07-21 | Eingeleitet | Goldman | Neutral |
| 2015-07-21 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Seres Therapeutics Inc Aktie (MCRB) Neueste Nachrichten
Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World
Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023) - Yahoo Finance
Canaccord Genuity Group Reiterates "Buy" Rating for Seres Therapeutics (NASDAQ:MCRB) - MarketBeat
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Seres Therapeutics reports key Q3 2024 milestones - Investing.com
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... - Yahoo Finance
Seres Therapeutics Reports Q3 2024 Results and Strategic Progress - TipRanks
Seres reports Q3 EPS from continuing operations (33c), consensus (24c) - TipRanks
Seres Therapeutics expects cash to fund operations into Q4 of 2025 - TipRanks
Seres Therapeutics Faces Nasdaq Challenge Amid Trial Success - TipRanks
Seres Therapeutics: Q3 Earnings Snapshot - New Haven Register
Seres Therapeutics reports Q3 EPS 58c, consensus (24c) - TipRanks
Seres Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Seres Therapeutics (MCRB) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 - The Manila Times
Seres Therapeutics Q3 2024 Earnings Call: MCRB Sets Key November Date | MCRB Stock News - StockTitan
Seres Therapeutics chief legal officer sells $2,939 in stock By Investing.com - Investing.com Australia
Seres Therapeutics exec von Moltke sells $2,991 in stock By Investing.com - Investing.com Canada
Seres Therapeutics executive sells shares worth $2,058 By Investing.com - Investing.com Canada
Seres Therapeutics executive sells shares worth $2,058 - Investing.com India
Seres Therapeutics executive sells stock for $2,749 By Investing.com - Investing.com Australia
Seres Therapeutics CEO Eric D. Shaff sells $6,036 in stock By Investing.com - Investing.com South Africa
Seres Therapeutics CEO Eric D. Shaff sells $6,036 in stock - Investing.com India
Seres Therapeutics chief legal officer sells $2,939 in stock - Investing.com India
Seres Therapeutics exec von Moltke sells $2,991 in stock - Investing.com
Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 17% of holdings value - Simply Wall St
This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - MSN
Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $5.08 Consensus Price Target from Analysts - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Stock Rating Lowered by JPMorgan Chase & Co. - MarketBeat
Seres cut to underweight by JP Morgan on Vowst sale - MSN
Seres cut to underweight by JP Morgan on Vowst sale (NASDAQ:MCRB) - Seeking Alpha
Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Seres Therapeutics Inc (MCRB)’s stock price range in the last year - US Post News
Seres Therapeutics (NASDAQ:MCRB) Stock Crosses Below 50 Day Moving AverageHere's What Happened - MarketBeat
Investor’s Delight: Seres Therapeutics Inc (MCRB) Closes Strong at 0.81, Up 4.77 - The Dwinnex
The time has not yet come to remove your chips from the table: Seres Therapeutics Inc (MCRB) - SETE News
Introducing Our Rant Against Seres Therapeutics Inc - US Post News
Seres Therapeutics gains amid takeover speculation - MSN
Seres Therapeutics Inc [MCRB] is -44.91% lower this YTD. Is it still time to buy? - The DBT News
An analyst sees good growth prospects for Seres Therapeutics Inc (MCRB) - SETE News
Seres Therapeutics Inc (MCRB) Stock: A Year of Declines and Increases - The InvestChronicle
Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 12% of holdings value - Yahoo Finance
Is Seres Therapeutics Inc (MCRB) a good investment opportunity? - US Post News
Gaining Ground: Seres Therapeutics Inc (MCRB) Closes Higher at 0.85, Up 1.35 - The Dwinnex
Nestlé agrees to buy microbiome therapy Vowst from Seres - MSN
Seres Therapeutics Inc (MCRB) is looking forward to a strong quarter - SETE News
Seres Therapeutics Inc (MCRB) may enjoy gains as insiders got busy in the recent days - Knox Daily
5 Best Microbiome Companies (November 2024) - Securities.io
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A - GlobeNewswire
Understanding Seres Therapeutics Inc Inc. (MCRB) Price Performance Through Chart Patterns - The InvestChronicle
Finanzdaten der Seres Therapeutics Inc-Aktie (MCRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):